TY  - JOUR
AU  - AlShehry, Nawal Faiez
AU  - Shanker, Raja
AU  - Zaidi, Syed Ziauddin Ahmed
AU  - AlGhmlas, Fahad
AU  - Motabi, Ibraheem Hussein
AU  - Iqbal, Shahid
AU  - Butt, Ahmad Ali
AU  - AlShehri, Hassan
AU  - Tailor, Imran Khan
AU  - Altaf, Syed Yasir
AU  - AlGhamdi, Mubarak
AU  - Marie, Mohammed
AU  - AlFayez, Mansour
AU  - Al Zahrani, Kamal
AU  - Dwaimah, Mohammed
AU  - Al-Halouli, Tahani
AU  - Al-Shakweer, Wafaa
AU  - AlShehery, Maied Zaher
AU  - Zaidi, Abdul Rehman Zia
AU  - Gill, Atta Munawar
AU  - Albtoosh, Belal Mohammed
AU  - Ahmed, Musab
PY  - 2021
DA  - 2021/11/12
TI  - Role of 18F-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography Imaging in the Prediction of Prognosis in Patients With Indolent Lymphoma: Prospective Study
JO  - JMIR Form Res
SP  - e24936
VL  - 5
IS  - 11
KW  - positron emission tomography
KW  - lymphoma
KW  - prognosis
KW  - indolent lymphoma
KW  - SUVmax
KW  - Deauville criteria
AB  - Background: The role of fluorodeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) in indolent lymphoma has been minimally studied. Objective: This study aims to assess the value of FDG-PET/CT in predicting the prognosis of indolent lymphoma. Methods: We prospectively recruited 42 patients with indolent lymphoma. A total of 2 patients were excluded, and 40 underwent baseline PET/CT and follow-up at various time points. A total of 9 patients were observed only, 7 received 4 doses of rituximab alone, and 24 received chemoimmunotherapy. Metabolic response on follow-up PET/CT was assessed using the maximum standardized uptake value (SUVmax) and Deauville criteria (DC). We aimed to obtain the best SUVmax and DC to predict optimal survival rates, risk stratification, and optimize therapeutic strategies. The mean follow-up from the initial diagnosis was 33.83 months. Results: SUVmax <4.35 at interim PET/CT provided the best discrimination, with a progression-free survival (PFS) of 100% and a median survival time of 106.67 months compared with SUVmax ≥4.35 (P=.04), which had a PFS of 43.8% and a median survival time of 50.17 months. This cutoff was also valuable in predicting overall survival at baseline, that is, 100% overall survival with baseline SUVmax <4.35, versus 58.4% for SUVmax ≥4.35 (P=.13). The overall survival of patients with a baseline DC score <3.0 was 100%, with a median overall survival of 106.67 months. Conclusions: We demonstrated the utility of PET/CT in indolent lymphomas. SUVmax (<4.35 vs ≥4.35) on interim PET/CT performed best in predicting PFS. 
SN  - 2561-326X
UR  - https://formative.jmir.org/2021/11/e24936
UR  - https://doi.org/10.2196/24936
UR  - http://www.ncbi.nlm.nih.gov/pubmed/34508363
DO  - 10.2196/24936
ID  - info:doi/10.2196/24936
ER  -